Our Research Members
Assistant Professor, Department of Family and Community Medicine
Scientist, Markham Diabetes Game Changing Initiative, and Health for All Family Health Team, Markham Stouffville Hospital
Research Associate, Connected Health and Wellness Project
Adjunct Professor, Department of Psychology, York University
379 Church Street
Markham, ON L6B 0T1
I am a Clinical Health Psychologist, and Assistant Professor in the Department of Family and Community Medicine. I have expertise in developing and implementing technology-supported behavioural interventions for obesity, and multiple health behaviour change, for chronic disease prevention. The goal of this line of research is to reduce the intesity of established face-to-face interventions, while preserving their efficacy, extending their community reach, and improving patient-provider communication. I am currently involved with the development of a large community-based diabets prevention initiative in Markham (Markham Diabetes Game Changining Initiative), and serve as the co-lead of the primary care component of this intervention.
Assistant Professor, Department of Physiology
I have strong research interests in the area of fetal maternal health and developmental origins of disease. I have several manuscripts on the development of the placenta and trophoblast cell lineages and on hypertensive disorders of pregnancy, such as preeclampsia. My interest in diabetes is in gestational diabetes, often found in conjunction with preeclampsia and the acute and chronic affect on the child, relating to the increased risk of developing type II diabetes. I apply a systems biology approach involving the generation and integration of proteomics, transcriptional and epigenetic data sets. I apply computational models to identify different molecular disease classes and mechanisms of gene regulation. I have several papers on the inter species comparisons of human and mouse tissues and disease models to understand the similarities and develop improved disease models for research. I am proposing to work with animal models of gestational diabetes and compare these results to human samples from bio banked placental material of patients with gestational diabetes. My goal is to develop better bio markers to determine the likelihood of developing diabetes after pregnancy.
Assistant Professor, Department of Surgery
Associate Scientist, Keenan Research Centre for Biomedical Science
iBEST, Research Program
Plastic, Reconstructive and Aesthetic Surgeon, St. Michael’s Hospital
Adjunctive Professor, Yeates School of Graduate Studies, Ryerson University
Developing optical technologies to assess tissue viability in the diabetic lower extremity. The aim is to develop novel devices in the prevention, diagnosis and management of Diabetic Foot Ulcers (DFU’s). The research laboratory is a combination of physics, engineering and clinical translation with the aim to have a direct impact on the lives of patients.
Assistant Professor, Faculty of Pharmacy
Several members of the nuclear hormone receptor superfamily have been implicated in protecting against diseases associated with the metabolic syndrome. For example, from data obtained using animal models, it appears the liver X receptors (LXRα and LXRB) are protective against atherosclerosis, dyslipidemia, and diabetes. The current focus of the Cummins lab is on the study of these nuclear hormone receptors and their roles in regulating glucose metabolism. Recently, we have shown that LXR is involved in the regulation of cholesterol conversion to glucocorticoids in the adrenal gland and are investigating the influence of this finding on glucose metabolism and the onset of type 2 diabetes. We are also exploring the link between LXR and the deposition of cholesterol in the glomeruli of the kidney in diabetic nephropathy.
Professor, Laboratory Medicine and Pathobiology, Faculty of Medicine
Senior Scientist, Advanced Diagnostics Division, Toronto General Research Institute, University Health Network
Staff Pathologist, Laboratory Medicine and Pathobiology, Toronto General Hospital, University Health Network
101 College Street
Toronto, ON M5G 1L7
The goal of Dr. Cybulsky’s research program is to elucidate novel cellular and molecular mechanisms regulating intimal macrophage burden at early stages of atherosclerosis. The vision is to use this information to develop new therapies to inhibit the progression of early atherosclerotic lesions to advanced plaques. Individuals with known risk factors for atherosclerosis would benefit from such therapies because complications arising from advanced plaques cause myocardial infarction and stroke, and therapies that inhibit disease progression would alleviate the morbidity and mortality associated with atherosclerosis. Our research program to reduce intimal macrophages in early atherosclerotic lesions and inhibit lesion progression focuses on several aspects of myeloid cell biology including macrophage exit from atherosclerotic lesions, inhibition of monocyte recruitment, macrophage proliferation and survival in early lesions and understanding how systemic risk factors influence macrophage gene expression triggered by pro-inflammatory stimuli. Previous research has focused on hypercholesterolemia, a key risk factor for atherosclerosis; however, future studies will also include hyperglycemia and advanced glycation endproducts, which are found in patients with diabetes. The burden of diabetes, particularly adult onset or type II diabetes, is increasing, as is its contribution to atherosclerosis-related conditions.
Professor, Department of Immunology; Department of Medical Biophysics
Program in Genetics and Genome Biology, Hospital for Sick Children
The objective of our research program is to define the genetic and environmental factors driving autoimmune mediated targeting of islet cells and to use this information to design and test therapeutics that prevent, block progression of or reverse type 1 diabetes. We have taken a multidisciplinary approach to genetic, genomic and immunological analysis of T1D risk in a well-validated mouse models, focusing on dissection of the complex genetics to provide insight into human T1D pathogenesis. We have extended these studies of the role of sex and of intestinal commensal bacteria on modifying genetic risk, and application of discoveries in rodent models to large, prospective cohort study of environmental determinants of T1D in genetically at risk children.
Assistant Professor, Department of Medicine, Division of Endocrinology and Metabolism
Staff Physician, University Health Network/Mount Sinai Hospital
200 Elizabeth St., Eaton Building, 12EN
Toronto, ON M5G 2C4
Phone: 416-340-4800 x8094
I am interested in obesity and insulin resistance. More specifically I aim to assess the role of the central nervous system in mediating various metabolic processes in humans in responses to drugs and peptides. Another avenue of research I will explore is investigating the etiology of obesity, its metabolic complications and response to treatment. I aim to utilize a combination of integrative in vivo physiology, genetic and pharmacological approaches to answer these research questions with the ultimate aim of potentially developing novel therapies for metabolic disorders.
Practice Leader-Clinical Nutrition, Allied Health, University Health Network
399 Bathurst Street, 1WW443
Toronto, ON M5T 2S8
Phone: 416-603-5800 x5973
I am interested in research that focuses on diabetes self-care management (DSM).
As part of interprofessional research teams, I have studied the effectiveness of DSM education programs, utilization and attrition such programs, food insecurity in Canadians with diabetes, and gender differences, psychosocial and clinical factors that help us better understand and serve those affected by diabetes.
Assistant Professor, Department of Surgery
Vascular Surgeon, St. Michael’s Hospital
Scientist, Li Ka Shing Knowledge Institute, St. Michael’s Hospital
Adjunct Scientist, Institute for Clinical Evaluative Sciences
I pursue population-based health services research focusing on patients with diabetes who undergo lower limb amputation. I am interested in better characterizing the epidemiology, outcomes, health-resource use and costs of lower limb amputation in diabetic patients as well as limb preservation therapies. The purpose of this work is to inform population-level interventions to reduce diabetes-related foot complications.
Professor, Department of Medicine, Division of Endocrinology & Metabolism
Senior Scientist, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital
Research in the Drucker lab is focused on understanding the biology of gut hormones, with a major focus on GIP and the glucagon-like peptides. The lab studies how glucagon, GIP, GLP-1, and GLP-2 regulate energy homeostasis, metabolic control, and cardiovascular function via effects on the gastrointestinal tract, pancreas, cardiovascular system and central nervous system. Specific projects elucidate novel mechanisms of glucagon, GIP, GLP-1 and GLP-2 action through studies of their respective receptors in peripheral tissues. Research staff utilize a combination of techniques that involve studies of signal transduction, generation of transgenic or knockout mice, and studies of rodent models of peptide hormone action with a focus on diabetes, obesity, endocrine systems, and intestinal disease.
Associate Professor and Canada Research Chair in Nutrigenomics; Department of Nutritional Sciences, Faculty of Medicine
150 College Street
Toronto, ON M5S 3E2
The overall goal of my research program in nutrigenomics is to elucidate the genetic basis for variability in dietary response on cardiometabolic disease. We are also interested in identifying the genetic determinants of and dietary preferences and eating behaviours as they relate to obesity and type 2 diabetes. Our research program employs metabolomics, proteomics and genomics to study the effects of diet on human health. This approach will help us to understand how genetic and dietary factors interact to regulate various metabolic and biochemical pathways involved in the development of chronic diseases, such as type 2 diabetes. We are currently investigating the role of genetic polymorphisms affecting innate immunity and inflammation on components of the metabolic syndrome. Other research projects focus on identifying the genes influencing sugar and carbohydrate consumption in lean and obese individuals.
Associate Professor, Department of Medicine
Director, Cardiology Research, Division of Cardiology
Director, Clinical Trials, Peter Munk Cardiac Centre, University Health Network
Scientist, Li Ka Shing Knowledge Institute, St. Michael’s Hospital
585 University Avenue, Room 4N474
Toronto, ON M5G 2N2
Diabetes Mellitus and Cardiovascular Disease: The main focus is the evaluation of diabetic patients with coronary artery disease, acute coronary syndromes and heart failure. We have examined the role of advanced multi-modal imaging in developing novel compounds to treat atherosclerosis in diabetic patients. I have conducted large-scale clinical trials such as the FREEDOM Trial which evaluated the optimal strategy required for the management of coronary artery disease. Our goal for the future is to develop a collaborative coordinating center to address the important clinical questions revolving around diabetes and heart disease.
Associate Professor, Departments of Medicine, Obstetrics & Gynecology, Health Policy, Management and Evaluation; Division of Endocrinology & Metabolism
60 Murray St., Room 5027
Toronto, ON M5T 3L9
Main research interest is in the area of diabetes in pregnancy.
We are currently conducting a multi-centre randomized controlled trial of metformin use in women with type 2 diabetes in pregnancy (MiTy trial).
I am also involved in studies looking at the placental transfer of diabetes drugs in pregnancy, the transfer of diabetes drugs into breast milk, and administrative databases looking at women with diabetes in pregnancy in Ontario.
Professor, Department of Physiology; Director, Collaborative Program In Neuroscience, School of Graduate Studies
The Feng lab is interested in understanding the mechanisms underlying synapse development and synaptic transmission using various in vitro and in vivo animal models. The major lines of research in the Feng Lab include 1) identifying the roles of ion channels in neurons and pancreatic cells under physiological and pathophysiological conditions, 2) determining the regulatory mechanisms of the ion channels, and 3) understanding neuronal control of hormone secretion in control and diabetic rodent models. The technical expertise in the Feng lab includes patch-clamp recordings, dynamic ratiometric imaging, confocal imaging, molecular biology and biochemistry.
Associate Professor, Department of Laboratory Medicine & Pathobiology
Senior Scientist, Toronto General Hospital Research Institute
Our lab studies the role of microRNAs in controlling vascular inflammation. We have a particular interest in determining the role of circulating microRNAs in disease pathogenesis, and exploring their use as biomarkers. We are studying mouse models of diabetic cardiomyopathy to define disease mechanisms that involve microRNAs and we are identifying circulating microRNA biomarkers in human patient cohorts with diabetes, diabetic cardiomyopathy and/or end-stage renal disease.
Professor, Division of Cardiology, Department of Medicine
Research Director, University Health Network and Mount Sinai Hospital Division of Cardiology
Chair, Board of Trustees, Banting Research Foundation
Deputy Physician-in-Chief, Research, Mount Sinai Hospital
Canada Research Chair in Integrative Cardiovascular Biology
600 University Avenue, Suite 1614
Toronto, ON M5G 1X5
The general theme of the Floras Clinical Cardiovascular Physiology Laboratory has been the elucidation of mechanisms responsible for initiation and progression of cardiovascular and related diseases in humans, through interdisciplinary patient oriented research.
Neural and intrinsic cardiovascular regulation is studied using: microneurographic recordings of sympathetic nerve discharge directed at resistance vessels, tracer kinetic methods to estimate total body norepinephrine spillover, spectral analysis of heart rate variability and baroreflex sensitivity for heart rate, plethysmographic methods for assessing blood flow, and ultrasonic methods for quantifying endothelium dependent and independent vasodilatation.
These methods have been applied to research questions concerning normal health and aging, and to conditions such as heart failure, sleep apnea, hypertension, renal failure, pulmonary hypertension, diabetes (in collaboration with Drs. Zinman, Millar and Meneilly), menopause and cirrhosis.
Professor, Department of Medical Biophysics
Senior Scientist, Tanz Centre for Research in Neurodegenerative Diseases
Increasing evidence now points to the deposition and cytotoxicity of islet amyloid polypeptide aggregates as major contributors to loss of beta cell mass and ultimately the progression to type 2 diabetes. Amyloid aggregation may also contribute to graft failure following islet transplantation in type 1 diabetes patients. Therefore, our research involves devising new ways to inhibit islet amyloid aggregation and protect beta cells, thereby slowing or preventing onset of type 2 diabetes and improving islet graft survival.
Assistant Professor, Department of Laboratory Medicine & Pathobiology
Clinical Biochemist, Department of Clinical Pathology, Sunnybrook Health Sciences Centre
2075 Bayview Ave., Room B204
Toronto, ON M4N 3M5
Phone: 416-480-6100 x89571
To study the molecular relationship between vitamin D endocrine system and diabetes.
Professor, Departments of Medicine and Physiology
1 King's College Circle
Toronto, ON M5S 1A8
Research in the Gaisano lab is focused on molecular mechanisms regulating exocytosis, employing islet cells as models. We were one of the firsts to demonstrate that SNARE proteins originally found to mediate neurotransmitter release are conserved in non-neuronal cells, including the pancreatic islet to regulate secretion. We contributed to the original work showing SNARE protein regulation of insulin granule exocytosis, and subsequently contributed much of the work showing how SNARE proteins physically and functionally interact with beta-cell ion channels (Kv, KATP, Ca2+) to regulate the intricate sequence of ion fluxes, membrane potential and exocytotic fusion events leading to secretion. Current efforts are directed at: 1) SNARE proteins regulation of newcomer granule exocytosis and compound insulin granule fusion, and employing such molecules by viral gene transfer to rescue type 2 diabetes; 2) excitosome formation of SNAREs with Kv and Ca2+ channels during insulin granule docking and priming; and 3) islet alpha cell secretory mechanisms and crosstalk with beta- and delta-cells in health and their dysregulation in diabetes. This lab has in place a full spectrum of state-of-the-art single islet cell analyses for rodent and human islets, including patch clamp electrophysiology and capacitance measurements on dispersed cells and intact islets within pancreas slices, imaging of single granule exocytosis by TIRFM, single islet cell (beta, alpha and delta cells) imaging within whole islet by confocal and multi-photon microscopy, and high-resolution FRET analysis of molecular interactions.
This lab also has full capabilities to perform assays for in vivo glucose homeostasis, including glucose clamps and surgical pancreatic duct perfusion of viruses for in vivo rescue of diabetic rodent models; islet cell biology assays, including islet isolation, islet perifusion secretory assays, assessment of intact islets within pancreatic slices in diabetic models, E.M.; biochemistry (immunoprecipitation), molecular biology and viral gene transfer (adeno/AAV/lentivirus).
Professor, Department of Physiology and Department of Medicine
The primary theme of A.G.’s research is the investigation of the effects of excess circulating energy substrates, in particular free fatty acids, on insulin action, secretion and kinetics, and the implication of these effects for the pathogenesis of diabetes. Secondary themes of research are the studies of the effects of nutrient and insulin excess in animal models of atherosclerosis and cancer .